NorthCrest Asset Manangement LLC Buys 6,440 Shares of Pfizer Inc. (NYSE:PFE)

NorthCrest Asset Manangement LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 16.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,391 shares of the biopharmaceutical company’s stock after acquiring an additional 6,440 shares during the period. NorthCrest Asset Manangement LLC’s holdings in Pfizer were worth $1,150,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PFE. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PFE shares. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Down 1.3%

NYSE PFE opened at $24.51 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a 50 day moving average of $23.06 and a 200-day moving average of $24.95. The company has a market cap of $139.35 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.02%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.